Form 8-K - Current report:
SEC Accession No. 0001867096-25-000031
Filing Date
2025-02-24
Accepted
2025-02-24 08:09:24
Documents
16
Period of Report
2025-02-24
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K xers-20250224.htm   iXBRL 8-K 30071
2 EX-99.1 exh991pressreleasedatedfeb.htm EX-99.1 14090
7 picture1reviseda.jpg GRAPHIC 4446
  Complete submission text file 0001867096-25-000031.txt   210903

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xers-20250224.xsd EX-101.SCH 2036
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT xers-20250224_def.xml EX-101.DEF 14916
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xers-20250224_lab.xml EX-101.LAB 26174
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xers-20250224_pre.xml EX-101.PRE 15570
18 EXTRACTED XBRL INSTANCE DOCUMENT xers-20250224_htm.xml XML 2833
Mailing Address 1375 WEST FULTON STREET, SUITE 1300 CHICAGO IL 60607
Business Address 1375 WEST FULTON STREET, SUITE 1300 CHICAGO IL 60607 844-445-5704
Xeris Biopharma Holdings, Inc. (Filer) CIK: 0001867096 (see all company filings)

EIN.: 871082097 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40880 | Film No.: 25654290
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)